contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls {
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


fleries-portfolio-company-anacardio-reports-positive-results-from-phase-1b-study-of-ac01-in-patients-with-heart-failure-and-reduced-ejection-fraction-and-announces-sek-205-million-financing-round

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

alternatePageUrls

imgUrl

description

Flerie is an active long-term life science investor with a focus on biotechnology and pharmaceutical investments globally. The company is based in Stockholm and London and manages a portfolio of investments in Europe, Israel and the USA. The main focus is on providing organizations that primarily operate in drug development with services and resources. Flerie was founded in 2011 and has its headquarters in Stockholm.

DISCLAIMER: HC ANDERSEN CAPITAL RECEIVES PAYMENT FROM INDEX PHARMACEUTICALS FOR A CORPORATE VISIBILITY/DIGITAL IR SUBSCRIPTION AGREEMENT. Dansk:  InDex Pharmaceuticals er en farmaceutisk udviklingsvirksomhed med fokus på immunologiske sygdomme, hvor der er et stort udækket medicinsk behov for nye behandlingsmuligheder. Virksomhedens førende aktiv er lægemiddelkandidaten cobitolimod, som er i klinisk fase 3 for behandling af moderat til svær colitis ulcerosa - en invaliderende, kronisk betændelse i tyktarmen. InDex har også udviklet en platform af patentbeskyttede stoffer i opdagelsesstadiet, såkaldte DNA-baserede ImmunoModulatory Sequences (DIMS), med potentiale til at blive brugt til behandling af forskellige immunologiske sygdomme. InDex er baseret i Stockholm, Sverige. Selskabets aktier (ticker INDEX) handles på Nasdaq First North Growth Market Stockholm. English:  InDex Pharmaceuticals is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The company’s lead asset is the drug candidate cobitolimod, which is in late-stage clinical development for the treatment of moderate to severe ulcerative colitis – a debilitating, chronic inflammation of the large intestine. InDex has also developed a platform of patent-protected discovery stage substances, so-called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in the treatment of various immunological diseases. InDex is based in Stockholm, Sweden. The company’s shares (ticker INDEX) are traded on Nasdaq First North Growth Market Stockholm.

Flerie

AnaCardio has successfully completed Part A of the phase 1b/2a GOAL-HF1 study of its novel, selective oral ghrelin receptor agonist in patients with heart failure. AC01 was well-tolerated, there...

<div class="mfn-body"><p>AnaCardio has successfully completed Part A of the phase 1b/2a GOAL-HF1 study of its novel, selective oral ghrelin receptor agonist in patients with heart failure. AC01 was well-tolerated, there was clear target engagement and exploratory pharmacodynamic measurements indicated increased contractility. This will be further evaluated in Part B of the ongoing trial, in the cohort expansion phase, due to start in early 2025. </p><p>In conjunction with this important clinical milestone, the company has completed a SEK 205 M Series A extension financing round, co-led by Novo Holdings, Pureos Bioventures and Sound Bioventures, with participation from current investors Flerie, Industrifonden and Fredrik and Ann-Helene Ljungström.</p><p>“We are pleased that given these encouraging results, AC01 can now move into the next phase of clinical development: We also welcome the new investors which further strengthens the syndicate. AnaCardio is now in an excellent position and one step closer to bringing a novel contractile agent to heart failure patients”, commented Mark Quick, Partner at Flerie.</p></div><div class="mfn-footer mfn-contacts mfn-29e5a9386325"><p><strong>For more information:</strong></p><p>Ted Fjällman, CEO<br>Email: ir@flerie.com</p></div><div class="mfn-footer mfn-about mfn-5793c5c817d4"><p><strong class="mfn-heading-1">Flerie in brief</strong><br>Flerie is an active long-term life science investor, with a broad and diversified portfolio of innovative companies based on pioneering science. We invest in product development and commercial growth&nbsp;opportunities&nbsp;globally alongside other leading investors, focusing predominantly on private&nbsp;companies&nbsp;that are otherwise difficult to access. Flerie’s active ownership model, broad network and resources support and accelerate the development of the portfolio projects, creating value for shareholders. Flerie AB’s ordinary share is listed on Nasdaq Stockholm with the ticker FLERIE. For further information please visit www.flerie.com</p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong><br><a rel="noopener" href="https://storage.mfn.se/6356eda3-e077-4411-80f9-90390811ad38/fleries-portfolio-company-anacardio-reports-positive-results-from-phase-1b-study-of-ac01-in-patients-with-heart-failure-and-reduced-ejection-fraction-and-announces-sek-205-million-financing-round.pdf" class="mfn-generated mfn-primary">Flerie’s portfolio company AnaCardio reports positive results from phase 1b study of AC01 in patients with heart failure and reduced ejection fraction, and announces SEK 205 million financing round</a></p></div>

Flerie’s portfolio company AnaCardio reports positive results from phase 1b study of AC01 in patients with heart failure and reduced ejection fraction, and announces SEK 205 million financing round